Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3111-3119

  Lloberas, Núria ^a,c   Torras, Joan ^a   Alperovich, Gabriela ^a   Cruzado, Josep M ^a   Giménez Bonafé, Pepita ^b   Herrero Fresneda, Immaculada ^a   Franquesa, Marcella ^a   Rama, Inés ^a   Grinyó, Josep M ^a  

^a IDIBELL Hospital Universitari Bellvitge   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Fibrosis; Immunosuppression; Inflammation; Renal toxicity

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GLYCOPROTEIN P; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY TUBULE DISORDER; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UREA BLOOD LEVEL;

ANIMALS; APOPTOSIS; CALCINEURIN; CYCLOSPORINE; DRUG INTERACTIONS; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; KIDNEY; MALE; P-GLYCOPROTEIN; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIROLIMUS; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52449108063     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn223     Document Type: Article

References (53)

1. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
2. Young BA, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439-448
3. Thomas SE, Andoh TF, Pichler RH et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897-908
4. Pirsch JD, Miller J, Deierhoi MH et al. FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983
5. Khanna AK, Hosenpud JS, Plummer MS et al. Analysis of transforming growth factor-beta and profibrogenic molecules in a rat cardiac allograft model treated with cyclosporine. Transplantation 2002; 73: 1543-1549
6. Andoh TF, Lindsley J, Franceschini N et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311-316
7. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
8. Nankivell BJ, Chapman JR, Bonovas G et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457-1459
9. Jain S, Bicknell GR, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000; 87: 1563-1568
10. Sunderkotter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-422
11. Podder H, Stepkowski SM, Napoli KL et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071
12. McAlister VC, Gao Z, Peltekian K et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-377
13. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6: 1991-1999
14. Meier-Kriesche HU, Steffen BJ, Chu AH et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4: 2058-2066
15. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273-2280
16. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606
17. Rao US, Scarborough GA. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 1994; 45: 773-776
18. del Moral RG, Andujar M, Ramirez C et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein over expression, and relationships with intrarenal angiotensin II deposits. Am J Pathol 1997; 151: 1705-1714
19. Koziolek MJ, Riess R, Geiger H et al. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60: 156-166
20. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080
21. Hochman JH, Yamazaki M, Ohe T et al. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 2002; 3: 257-273
22. Hauser IA, Koziolek M, Hopfer U et al. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998; 54: 1139-1149
23. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-429
24. Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404
25. Herrero-Fresneda I, Torras J, Cruzado JM et al. Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127-137
26. Franquesa M, Alperovich G, Herrero-Fresneda I et al. Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure. Gene Ther 2005; 12: 1551-1558
27. Nielsen FT, Ottosen P, Starklint H et al. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003; 18: 491-496
28. Groth CG, Backman L, Morales JM et al. Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042
29. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340
30. Eisen H, Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 2004; 23: S207-S213
31. Brook NR, Waller JR, Bicknell GR et al. Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage. Transplant Proc 2005; 37: 837-838
32. Shihab FS, Bennett WM, Yi H et al. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111-119
33. Brook NR, Waller JR, Bicknell GR et al. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005; 125: 137-143
34. Kahan BD. The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194-202
35. Aicher L, Meier G, Norcross AJ et al. Decrease in kidney calbindin-D 28 kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochem Pharmacol 1997; 53: 723-731
36. Asai T, Nakatani T, Yamanaka S et al. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 2002; 74: 784-791
37. Assoian RK, Fleurdelys BE, Stevenson HC et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987; 84: 6020-6024
38. Weller PF. Human eosinophils. J Allergy Clin Immunol 1997; 100: 283-287
39. Newman SL, Henson JE, Henson PM. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages. J Exp Med 1982; 156: 430-442
40. Savill J. Apoptosis and the kidney. J Am Soc Nephrol 1994; 5: 12-21
41. Kim WH, Matsumoto K, Bessho K et al. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 2005; 166: 1017-1028
42. Ling H, Li X, Jha S et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14: 377-388
43. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
44. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999; 67: 614-619
45. Bicknell GR, Williams ST, Shaw JA et al. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 2000; 87: 1569-1575
46. Ozdemir BH, Ozdemir FN, Gungen Y et al. Role of macrophages and lymphocytes in the induction of neovascularization in renal allograft rejection. Am J Kidney Dis 2002; 39: 347-353
47. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
48. Diekmann F, Rovira J, Carreras J et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653-2660
49. Liu J, Brunner LJ. Chronic cyclosporine administration induces renal P-glycoprotein in rats. Eur J Pharmacol 2001; 418: 127-132
50. Lemahieu WP, Maes BD, Verbeke K et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs tacrolimus vs sirolimus. Am J Transplantation 2004; 4: 1514-1522
51. Shihab FS, Bennett WM, Yi H et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-1271
52. Hsiao P, Sasongko L, Link JM et al. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 2006; 317: 704-710
53. Kuppens IE, Breedveld P, Beijnen JH et al. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005; 23: 443-464